ANDA 65290, held by Hospira. Cefotaxime Sodium.
As of Nov 21, 2026, ANDA 65290 (Cefotaxime Sodium), held by Hospira, was first approved by FDA on Aug 11, 2006, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 11, 2006 | Original application | Approved | None posted |
| Cefotaxime SodiumEQ 500MG BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
| Cefotaxime SodiumEQ 1GM BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
| Cefotaxime SodiumEQ 2GM BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
| Jun 26, 2012 | Supplement 2Labeling | Approved | None posted |
| Aug 11, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters